

Mark M Moasser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9293646/publications.pdf>

Version: 2024-02-01

25
papers

1,561
citations

686830

13
h-index

610482

24
g-index

26
all docs

26
docs citations

26
times ranked

2684
citing authors

#	ARTICLE	IF	CITATIONS
1	Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. <i>Nature</i> , 2007, 445, 437-441.	13.7	853
2	Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver. <i>Science Translational Medicine</i> , 2010, 2, 16ra7.	5.8	154
3	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3584.	5.8	115
4	HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3. <i>Cancer Research</i> , 2018, 78, 3645-3658.	0.4	85
5	CD318 is a ligand for CD6. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6912-E6921.	3.3	67
6	A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src. <i>Cell Reports</i> , 2018, 25, 449-463.e4.	2.9	41
7	Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1472-1479.	0.8	31
8	HER family in cancer progression: From discovery to 2020 and beyond. <i>Advances in Cancer Research</i> , 2020, 147, 109-160.	1.9	27
9	Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. <i>Nature Cell Biology</i> , 2019, 21, 778-790.	4.6	24
10	Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 26, 1618-1625.	1.9	23
11	The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. <i>Scientific Reports</i> , 2021, 11, 9091.	1.6	20
12	Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3K and HDAC. <i>Journal of Investigative Dermatology</i> , 2021, 141, 364-373.	0.3	17
13	Effective treatment of HER2-amplified breast cancer by targeting HER3 and β 1 integrin. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 431-440.	1.1	15
14	Targeting HER2 by Combination Therapies. <i>Journal of Clinical Oncology</i> , 2018, 36, 808-811.	0.8	13
15	Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A. <i>Biochemical Pharmacology</i> , 2021, 183, 114317.	2.0	13
16	Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain. <i>Molecular Cancer Research</i> , 2021, 19, 957-967.	1.5	9
17	Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. <i>Cell Reports</i> , 2022, 38, 110291.	2.9	7
18	Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. <i>Cell Reports</i> , 2022, 38, 110285.	2.9	7

#	ARTICLE	IF	CITATIONS
19	Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. <i>Blood Advances</i> , 2022, 6, 2290-2302.	2.5	6
20	Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions. <i>Cancer Research</i> , 2022, 82, 2811-2820.	0.4	5
21	A TORC2–Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2805-2817.	1.9	4
22	Disentangling Multidimensional Spatio-Temporal Data into Their Common and Aberrant Responses. <i>PLoS ONE</i> , 2015, 10, e0121607.	1.1	1
23	Expression and purification of active human kinases using <i>Pichia pastoris</i> as a general-purpose host. <i>Protein Expression and Purification</i> , 2021, 179, 105780.	0.6	1
24	A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. <i>Cancer Research Communications</i> , 2022, 2, 570-576.	0.7	1
25	Loss of CDCP1 triggers FAK activation in detached prostate cancer cells. <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 350-366.	0.4	0